SCIENCE
A Pharmacological Model of TRPA1-Mediated
Nociception in Zebrafish for Therapeutic Discovery
Student researcher: Emre Coskun, Junior
Chronic pain exists in over 50 million American adults,
and it can have signiﬁcant eﬀects on an individual’s quality
of life. Chronic pain is often inadequately treated with
narcotic painkillers such as opioids. The long-term usage
of opioids leads to side eﬀects like overdose, tolerance,
and dependence, which decreases the number of eﬀective
treatments available for chronic pain. A better treatment
alternative would be non-narcotic analgesics that target the
local transmission of pain (nociception).
Nociception arising from exogenous (environmental)
and endogenous (internal) irritants is mediated by the
activation of the Transient Receptor Potential, subfamily
A1 (TRPA1) channel through calcium influx in sensory
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neurons. Although the TRPA1 channel is an analgesic target
for chronic pain, there are no inhibitors for it that have
been approved by the Food and Drug Administration. The
TRPA1 channel is present in both humans and zebraﬁsh.
In zebraﬁsh, this channel can be activated by chemical
irritants (agonists), which would result in an increase in
swimming behavior (hyperlocomotion). I hypothesized that
this hyperlocomotion can be used to screen novel antinociceptive drugs.
In my study, I utilized a TRPA1 agonist, ASP7663, to induce
hyperlocomotion in 5 days-post-fertilization (dpf) zebraﬁsh
larvae, as mentioned in Ganzen, Ko, and colleagues’ 2019
article in Scientiﬁc Reports, “A Critical Evaluation of
TRPA1-Mediated Locomotor Behavior in Zebraﬁsh as a
Screening Tool for Novel Anti-Nociceptive Drug Discovery.”
Therefore, the TRPA1-mediated hyperlocomotion modeled
chronic neuropathic pain in humans. Chemicals that could
block this hyperlocomotion would potentially treat chronic
pain. To determine the feasibility of my idea, I pre-treated
5-dpf zebraﬁsh larvae with HC030031, a known TRPA1
antagonist, before challenging them with the ASP7663
agonist. This pre-treatment blocked the ASP7663-induced
hyperlocomotion. My results suggest that ASP7663-induced
hyperlocomotion in 5-dpf zebraﬁsh larvae is an eﬀective
in vivo model for screening drugs that act like HC030031.
Identifying such compounds can lead to non-narcotic
treatment options for chronic pain.
Research advisors Yuk Fai Leung and Logan Ganzen
write: “Emre joined this project because of a Collaborative
Research Grant from the Purdue Institute for Integrative
Neuroscience. His work has contributed to our
understanding of how TRPA1 modulates neuropathic
pain and has resulted in the development of a zebraﬁsh
behavioral assay that can be used to identify novel nonopiate painkillers.”
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